




RealRate

PHARMACEUTICAL 2020

CytoDyn Inc.
Rank 330 of 358





PHARMACEUTICAL 2020

CytoDyn Inc.
Rank 330 of 358



The relative strengths and weaknesses of CytoDyn Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytoDyn Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 176% points. The greatest weakness of CytoDyn Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 221% points.

The company's Economic Capital Ratio, given in the ranking table, is -282%, being 319% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	5,369
Cost of Goods Sold	0
Intangible Assets	15,475
Liabilities, Current	26,926
Liabilities, Non-Current	2,862
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,731
Other Liabilities	0
Other Net Income	151
Other Revenues	0
Property and Equipment	29
Research and Development	42,490
Selling, General and Administrative Expense	12,117

Output Variable	Value in 1000 USD
Assets	20,874
Liabilities	29,788
Expenses	56,338
Revenues	0
Stockholders Equity	-8,914
Net Income	-56,187
Comprehensive Net Income	-56,187
Economic Capital Ratio	-282%